2929-LB: Implementing a FibroScan Clinic in Primary Care: A Pilot Program

Introduction and Objective: The rates of screening for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis-4 (FIB-4) index is slowly increasing in the primary care setting. Access to Vibration-Controlled Transient Elastography (FibroScan) remains a barrier in identifying high-risk MASLD and is currently underutilized. We evaluate an approach to implementation of a FibroScan workflow to increase screening in a Federally Qualified Health Center (FQHC). Methods: FibroScan clinics are scheduled two half days a month in an FQHC and staffed with two FibroScan certified physicians and one medical assistant. Patient selection is based on current American Diabetes Association (ADA) MASLD screening guidelines. Appointments are forty minutes in length and include a FibroScan, interpretation, and clinical management. Results: Table 1 shows process and outcome measures from the initial FibroScan clinics. Conclusion: Initial findings demonstrate the feasibility of implementing a FibroScan clinic workflow in primary care. Screening for high-risk MASLD has the potential for reduction in hepatology referrals. The availability of point-of care FibroScan provides an opportunity for integration of this validated imaging technique for liver fibrosis screening, especially in low resource settings. Disclosure Y. Bains: None. J. Shubrook: Advisory Panel; Current; Abbott Diabetes. Other - Doc Care Deputy EditorConsensus panel-liver health, screening early stage T1d, Technology in primary care; Current; American Diabetes Association. Advisory Panel; Current; Bayer AG, Boehringer Ingelheim International GmbH. Consultant; Ended; Corcept Therapeutics. Advisory Panel; Ended; Idorsia Pharmaceuticals Ltd. Advisory Panel; Current; Insulet Corporation. Advisory Panel; Ended; Madrigal Pharmaceuticals, Inc. Consultant; Current; Novo Nordisk, Sanofi.